Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals.

Baxter AE, Niessl J, Fromentin R, Richard J, Porichis F, Charlebois R, Massanella M, Brassard N, Alsahafi N, Delgado GG, Routy JP, Walker BD, Finzi A, Chomont N, Kaufmann DE.

Cell Host Microbe. 2016 Sep 14;20(3):368-80. doi: 10.1016/j.chom.2016.07.015. Epub 2016 Aug 18.

PMID:
27545045
2.

'I can coexist with HIV': a qualitative study of perceptions of HIV cure among people living with HIV in Guangzhou, China.

Ma Q, Wu F, Henderson G, Rennie S, Rich ZC, Cheng Y, Hu F, Cai W, Tucker JD.

J Virus Erad. 2016 Jul 1;2(3):170-4.

3.
4.
5.

Stem-loop binding protein is a multifaceted cellular regulator of HIV-1 replication.

Li M, Tucker LD, Asara JM, Cheruiyot CK, Lu H, Wu ZJ, Newstein MC, Dooner MS, Friedman J, Lally MA, Ramratnam B.

J Clin Invest. 2016 Aug 1;126(8):3117-29. doi: 10.1172/JCI82360. Epub 2016 Jul 25.

PMID:
27454292
6.

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART.

Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, Killian M, Epling L, Hoh R, Sinclair E, Hecht FM, Bacchetti P, Deeks SG, Lewin SR, Sékaly RP, Chomont N.

PLoS Pathog. 2016 Jul 14;12(7):e1005761. doi: 10.1371/journal.ppat.1005761. eCollection 2016 Jul.

7.

The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence.

Murray AJ, Kwon KJ, Farber DL, Siliciano RF.

J Immunol. 2016 Jul 15;197(2):407-17. doi: 10.4049/jimmunol.1600343. Review.

PMID:
27382129
8.

Targeted HIV-1 Latency Reversal Using CRISPR/Cas9-Derived Transcriptional Activator Systems.

Bialek JK, Dunay GA, Voges M, Schäfer C, Spohn M, Stucka R, Hauber J, Lange UC.

PLoS One. 2016 Jun 24;11(6):e0158294. doi: 10.1371/journal.pone.0158294. eCollection 2016.

9.

Splenic Damage during SIV Infection: Role of T-Cell Depletion and Macrophage Polarization and Infection.

Williams DW, Engle EL, Shirk EN, Queen SE, Gama L, Mankowski JL, Zink MC, Clements JE.

Am J Pathol. 2016 Aug;186(8):2068-87. doi: 10.1016/j.ajpath.2016.03.019. Epub 2016 Jun 18.

PMID:
27322772
10.

Advances in biosensing strategies for HIV-1 detection, diagnosis, and therapeutic monitoring.

Lifson MA, Ozen MO, Inci F, Wang S, Inan H, Baday M, Henrich TJ, Demirci U.

Adv Drug Deliv Rev. 2016 Aug 1;103:90-104. doi: 10.1016/j.addr.2016.05.018. Epub 2016 Jun 2. Review.

PMID:
27262924
11.

Coevolutionary Analysis Identifies Protein-Protein Interaction Sites between HIV-1 Reverse Transcriptase and Integrase.

Arachchilage MH, Piontkivska H.

Virus Evol. 2016 Jan;2(1). pii: vew002. Epub 2016 Feb 23.

12.

Synergies, tensions and challenges in HIV prevention, treatment and cure research: exploratory conversations with HIV experts in South Africa.

Moodley K, Rossouw T, Staunton C, Colvin CJ.

BMC Med Ethics. 2016 Apr 30;17(1):26. doi: 10.1186/s12910-016-0109-1.

13.

Regulation of Gag- and Env-Specific CD8+ T Cell Responses in ART-Naïve HIV-Infected Patients: Potential Implications for Individualized Immunotherapy.

Prebensen C, Lind A, Dyrhol-Riise AM, Kvale D.

PLoS One. 2016 Apr 29;11(4):e0153849. doi: 10.1371/journal.pone.0153849. eCollection 2016.

14.

Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line.

Kumar A, Abbas W, Colin L, Khan KA, Bouchat S, Varin A, Larbi A, Gatot JS, Kabeya K, Vanhulle C, Delacourt N, Pasquereau S, Coquard L, Borch A, König R, Clumeck N, De Wit S, Rohr O, Rouzioux C, Fulop T, Van Lint C, Herbein G.

Sci Rep. 2016 Apr 14;6:24090. doi: 10.1038/srep24090.

15.

Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa.

Phillips AN, Cambiano V, Revill P, Nakagawa F, Lundgren JD, Bansi-Matharu L, Mabugu T, Sculpher M, Garnett G, Staprans S, Becker S, Murungu J, Lewin SR, Deeks SG, Hallett TB.

J Infect Dis. 2016 Jul 1;214(1):73-9. doi: 10.1093/infdis/jiw120. Epub 2016 Mar 30.

16.

Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.

Ishizaka A, Sato H, Nakamura H, Koga M, Kikuchi T, Hosoya N, Koibuchi T, Nomoto A, Kawana-Tachikawa A, Mizutani T.

J Virol. 2016 May 27;90(12):5665-76. doi: 10.1128/JVI.03158-15. Print 2016 Jun 15.

PMID:
27030274
17.

Implications of prioritizing HIV cure: new momentum to overcome old challenges in HIV.

Tucker JD, Gilbertson A, Lo YR, Vitória M.

BMC Infect Dis. 2016 Mar 3;16:109. doi: 10.1186/s12879-016-1445-y.

18.

Elimination of HIV-1-infected cells by broadly neutralizing antibodies.

Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, Donahue DA, Lorin V, Casartelli N, Noël N, Lambotte O, Mouquet H, Schwartz O.

Nat Commun. 2016 Mar 3;7:10844. doi: 10.1038/ncomms10844.

19.

Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.

Sips M, Krykbaeva M, Diefenbach TJ, Ghebremichael M, Bowman BA, Dugast AS, Boesch AW, Streeck H, Kwon DS, Ackerman ME, Suscovich TJ, Brouckaert P, Schacker TW, Alter G.

Mucosal Immunol. 2016 Feb 17. doi: 10.1038/mi.2016.12. [Epub ahead of print]

20.

The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis.

Freedberg KA, Possas C, Deeks S, Ross AL, Rosettie KL, Di Mascio M, Collins C, Walensky RP, Yazdanpanah Y.

J Virus Erad. 2015;1(4):245-249. Epub 2015 Sep 27.

Items per page

Supplemental Content

Write to the Help Desk